Oral semaglutide: difference between revisions
Diff·revision 17 → 18·03:38, 19 Jul 2025
Difference between revision 17 and revision 18 of Oral semaglutide. 7 lines changed; the page grew by 807 bytes.
| Revision 17 — 06:26, 19 Jun 2025 LiraLotte (talk) add the receptor targets to the lead sentence 3,542 bytes ±0 | Revision 18 — 03:38, 19 Jul 2025 CategoryBot (talk) bot: add drug-class category 4,349 bytes +807 | ||
|---|---|---|---|
| 28 | The small-molecule agonists such as [[Orforglipron|orforglipron]] address the same problem differently: not being peptides, they need neither an enhancer nor fasting conditions.{{r|drucker2018}} | 28 | The small-molecule agonists such as [[Orforglipron|orforglipron]] address the same problem differently: not being peptides, they need neither an enhancer nor fasting conditions.{{r|drucker2018}} |
| 29 | 29 | ||
| + | 30 | == Analytical and handling notes == | |
| + | 31 | A tablet is a different analytical object from a lyophilised powder. Content uniformity, dissolution and the enhancer's own assay are part of its specification, none of which appears on a peptide [[Certificate of analysis|certificate of analysis]].{{r|usp1503}} | |
| + | 32 | ||
| + | 33 | Research-chemical supply of this formulation is uncommon, since a co-formulated tablet is a manufactured drug product rather than a bulk peptide, and reproducing it is a formulation exercise rather than a synthesis.{{r|reports}} | |
| + | 34 | ||
| 30 | == References == | 35 | == References == |
| 31 | {{reflist}} | 36 | {{reflist}} |
| ⋮ | ⋮ | ||
| 33 | <ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A, et al. "Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist." ''Science Translational Medicine'' 10(467):eaar7047 (2018). PMID 30429357.</ref> | 38 | <ref name="buckley2018">Buckley ST, Bækdal TA, Vegge A, et al. "Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist." ''Science Translational Medicine'' 10(467):eaar7047 (2018). PMID 30429357.</ref> |
| 34 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 39 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| + | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| + | 41 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 35 | 42 | ||
| 36 | == See also == | 43 | == See also == |